CCL19, CXCL8, CXCL10, CXCL13 (Approved for MS. Annualized relapse rate: 0.11 with ofatumumab, 0.22 with teriflunomide Modulates CXCL10.) Here, CXCL8 is linked to myeloid sarcoma.